|
|
|
|
Talking Point: Responding to trial emergencies
Patients taking part in a clinical trial will sometimes experience a medical emergency, at which point the potential need to unblind their treatment needs to be considered.Unblinding is only done when it is deemed essential for the patients by the subjects...
|
|
|
Manufacturing news in brief
Developments in the pharmaceutical manufacturing arena in the last week include facility news for Dr Reddy's, Dishman, W.Grace, Haselmeier and Fresenius Kabi, first-quarter results for Patheon and a new contract for Angel Biotech of the UK. UK contract...
|
|
|
Digital Pharma: Novartis' transplant community
Novartis has become the second pharma company to partner with PatientsLikeMe on an online community, working with the site on a section for people who have received organ transplants.It follows in the footsteps of UCB, which established the first pharma...
|
|
|
Brandcast strengthens healthcare team
Digital agency Brandcast Media has added two new members to its London-based team.Lily Max (pictured left) joins as video film producer, having previously worked with Brandcast on a freelance basis, and Kelly Vesty moves to the agency from Euro RSCG Life...
|
|
|
LEC appoints Matthew Baker
UK healthcare advertising agency Lane Earl Cox (LEC) has appointed Matthew Baker as deputy managing director.He joins LEC from Huntsworth Health, where he was director of digital communication and director of brand strategy. Matthew spent five years with...
|
|
|
Cephalon to develop new class of cancer drug
Pennsylvania-based Cephalon has signed a deal with the discovery arm of charity Cancer Research UK to develop a new class of cancer drug.The US biotech will collaborate with Cancer Research Technology (CRT) on small molecule inhibitors targeting Protein...
|
|
|
European approval for 'double strength' Faslodex
AstraZenecas Faslodex has expanded its European licence after winning approval to treat women with hormone receptor-positive breast cancer in a 500mg dose.Regulators passed the drug to be used at twice its previously licensed dose of 250mg, persuaded by...
|
|
|
GSKs Relovair moves into phase III
GlaxoSmithKline has started phase III asthma trials of Relovair, the respiratory treatment it is developing with San Francisco biopharma firm Theravance.Relovair combines GSKs inhaler Seretide, itself a combination of fluticasone and salmeterol, with an...
|
|
|
Rooftop raiders steal $76m of Lilly products
Thieves have made off with $75 million-worth of central nervous system, cardiovascular and cancer drugs from an Eli Lilly distribution facility in the US in a highly-organised heist which is thought to be the biggest ever affecting the pharmaceutical industry....
|
|
|
IMS adds countries to pharmerging hit-list
IMS Health has added 10 more countries to its list of pharmerging markets which represent the future of pharma industry growth.The original group of seven countries which IMS labelled pharmerging a few years ago - Brazil, Turkey, Russia, China, India, Mexico...
|
